CVM is working in partnership with other offices across the FDA and Division of Overall health and Human Expert services as Component of a complete-of-authorities reaction to this vital and rising situation. In February, in coordination with FDA’s Workplace of Regulatory Affairs, we took motion that will help ensure that any xylazine moving into